FK866

Catalog No. A11279

FK866是一种高度特异性的非竞争性烟酰胺磷酸核糖基转移酶抑制剂，代表一种诱导肿瘤细胞凋亡的新机制。

Product Citations

Takeshi Nakamura, .et al. Effects of NAD+ Synthesis Levels on Sirtuin 1 Deacetylase Activity in Mammalian Cells, Shimane Journal of Medical Science, 2022, 38 (2), 59-66
Takeshi Katayoshi, .et al. Restoring NAD + by NAMPT is essential for the SIRT1/p53-mediated survival of UVA- and UVB-irradiated epidermal keratinocytes, J Photochem Photobiol B, 2021, Jun 12;221:112238 PMID: 34130091
Yool Lee, .et al. Time-of-day specificity of anticancer drugs may be mediated by circadian regulation of the cell cycle, Sci Adv, 2021, 7
Peter M LoCoco, .et al. Pharmacological augmentation of nicotinamide phosphoribosyltransferase (NAMPT) protects against paclitaxel-induced peripheral neuropathy, eLife, 2017, 6: e29626 PMID: 29125463

Technical details

Catalog Num	A11279
M. Wt	391.5
Formula	C24H29N3O2
Purity	>98%
Storage	at -20°C 3 years Powder
CAS No.	658084-64-1
Synonyms	K 22.175, FK-866
SMILES	C1CN(CCC1CCCCNC(=O)/C=C/C2=CN=CC=C2)C(=O)C3=CC=CC=C3

Biological Activity

FK866是一种高度特异性的非竞争性烟酰胺磷酸核糖基转移酶抑制剂，代表一种诱导肿瘤细胞凋亡的新机制。

Targets

NMPRTase (Cell-free assay)
0.09 nM

Solubility *

In vitro (25°C)	DMSO	Insoluble
	Water	Insoluble
	Ethanol	77 mg/mL (196.67 mM)
In vivo	5% DMSO+40% PEG 300+5% Tween 80+50% ddH2O	3 mg/mL
* <1 mg/ml means slightly soluble or insoluble. * Please note that Adooq tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Preparing Stock Solutions

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
0.1 mM	25.54 mL	127.71 mL	255.43 mL
0.5 mM	5.11 mL	25.54 mL	51.09 mL
1 mM	2.55 mL	12.77 mL	25.54 mL
5 mM	0.51 mL	2.55 mL	5.11 mL

*The above data is based on the productmolecular weight 391.5. Batch specific molecular weights may vary from batch to batch due to solvent of hydration, which will affect the solvent volumes required to prepare stock solutions.